The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials
Open accessAbstract
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by IgE hyperproduction and eosinophilic inflammation. The anti-IgE antibody, omalizumab, has demonstrated efficacy in patients with CRSwNP and comorbid asthma previously. OBJECTIVE: Our aim was to determine omalizumab safety and efficacy in CRSwNP in phase 3 trials (POLYP 1 and POLYP 2). METHODS: Adults with CRSwNP with inadequate response to intranasal corticosteroids were randomized (1:1) to omalizumab or placebo and intranasal mometasone for 24 weeks. Coprimary end points included change from baseline to week 24 in Nasal Polyp Score (NPS) and Nasal Congestion Score. Secondary end points included change from baseline to week 24 in Sino-Nasal Outcome Test-22 (SNOT-22) score, University of Pennsylvania Smell Identification Test, sense of smell, postnasal drip, runny nose, and adverse events. RESULTS: Patients in POLYP 1 (n = 138) and POLYP 2 (n = 127) exhibited severe CRSwNP and substantial quality of life impairment evidenced by a mean NPS higher than 6 and SNOT-22 score of approximately 60. Both studies met both the coprimary end points. SNOT-22 score, University of Pennsylvania Smell Identification Test score, sense of smell, postnasal drip, and runny nose were also significantly improved for omalizumab versus placebo. In POLYP 1 and POLYP 2, the mean changes from baseline at week 24 for omalizumab versus placebo were as follows: NPS, -1.08 versus 0.06 (P < .0001) and -0.90 versus -0.31 (P = .0140); Nasal Congestion Score, -0.89 versus -0.35 (P = .0004) and -0.70 versus -0.20 (P = .0017); and SNOT-22 score, -24.7 versus -8.6 (P < .0001) and -21.6 versus -6.6 (P < .0001). Adverse events were similar between groups. CONCLUSION: Omalizumab significantly improved endoscopic, clinical, and patient-reported outcomes in severe CRSwNP with inadequate response to intranasal corticosteroids, and it was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
European Position Paper on Rhinosinusitis and Nasal Polyps 2020
Fokkens, W. J., Lund, V. J., Hopkins, C., Hellings, P. W., Kern, R., Reitsma, S., Toppila-Salmi, S., Bernal-Sprekelsen, M., Mullol, J., Alobid, I., et al. (2020) · Rhinology journal · doi:10.4193/rhin20.600 · Cited by 5,882
Self-citationPsychometric validity of the 22‐item Sinonasal Outcome Test
Hopkins, C., Gillett, S., Slack, R., Lund, V. J., & Browne, J. P. (2009) · Clinical Otolaryngology · doi:10.1111/j.1749-4486.2009.01995.x · Cited by 1,621
Bachert, C., Mannent, L., Naclerio, R. M., Mullol, J., Ferguson, B. J., Gevaert, P., Hellings, P., Jiao, L., Wang, L., Evans, R. R., et al. (2016) · JAMA · doi:10.1001/jama.2015.19330 · Cited by 794 · cited 1×
“2.(24,29,30) The full analysis set (FAS) included all randomized patients who received at least 1 dose of study drug according to assigned treatment group.”
Self-citationOmalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma
Gevaert, P., Calus, L., Van Zele, T., Blomme, K., De Ruyck, N., Bauters, W., Hellings, P., Brusselle, G., De Bacquer, D., van Cauwenberge, P., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.047 · Cited by 744
Self-citationNovel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study
Tokunaga, T., Sakashita, M., Haruna, T., Asaka, D., Takeno, S., Ikeda, H., Nakayama, T., Seki, N., Ito, S., Murata, J., et al. (2015) · Allergy · doi:10.1111/all.12644 · Cited by 710
Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis
Gevaert, P., Van Bruaene, N., Cattaert, T., Van Steen, K., Van Zele, T., Acke, F., De Ruyck, N., Blomme, K., Sousa, A. R., Marshall, R. P., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.07.056 · Cited by 629
Self-citationChronic Rhinosinusitis with Nasal Polyps
Stevens, W. W., Schleimer, R. P., & Kern, R. C. (2016) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2016.04.012 · Cited by 571
Hanania, N. A., Alpan, O., Hamilos, D. L., Condemi, J. J., Reyes-Rivera, I., Zhu, J., Rosen, K. E., Eisner, M. D., Wong, D. A., & Busse, W. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-9-201105030-00002 · Cited by 554
DeConde, A. S., Mace, J. C., Levy, J. M., Rudmik, L., Alt, J. A., & Smith, T. L. (2017) · The Laryngoscope · doi:10.1002/lary.26391 · Cited by 443
Cited by
International consensus statement on allergy and rhinology: rhinosinusitis 2021
Orlandi, R. R., Kingdom, T. T., Smith, T. L., Bleier, B., DeConde, A., Luong, A. U., Poetker, D. M., Soler, Z., Welch, K. C., Wise, S. K., et al. (2021) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22741 · Cited by 959
Self-citationHan, J. K., Bachert, C., Fokkens, W., Desrosiers, M., Wagenmann, M., Lee, S. E., Smith, S. G., Martin, N., Mayer, B., Yancey, S. W., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00097-7 · Cited by 628
Self-citationChronic Rhinosinusitis with Nasal Polyps and Asthma
Laidlaw, T. M., Mullol, J., Woessner, K. M., Amin, N., & Mannent, L. P. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2020.09.063 · Cited by 419
Self-citationBachert, C., Han, J. K., Wagenmann, M., Hosemann, W., Lee, S. E., Backer, V., Mullol, J., Gevaert, P., Klimek, L., Prokopakis, E., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.11.013 · Cited by 355
Self-citationBachert, C., Marple, B., Schlosser, R. J., Hopkins, C., Schleimer, R. P., Lambrecht, B. N., Bröker, B. M., Laidlaw, T., & Song, W.-J. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00218-1 · Cited by 327
Self-citationEosinophils in Health and Disease: A State-of-the-Art Review
Wechsler, M. E., Munitz, A., Ackerman, S. J., Drake, M. G., Jackson, D. J., Wardlaw, A. J., Dougan, S. K., Berdnikovs, S., Schleich, F., Matucci, A., et al. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.04.025 · Cited by 312
Mechanisms and pathogenesis of chronic rhinosinusitis
Kato, A., Schleimer, R. P., & Bleier, B. S. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.02.016 · Cited by 306
Kato, A., Peters, A. T., Stevens, W. W., Schleimer, R. P., Tan, B. K., & Kern, R. C. (2022) · Allergy · doi:10.1111/all.15074 · Cited by 305
Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps
Bachert, C., Bhattacharyya, N., Desrosiers, M., & Khan, A. H. (2021) · Journal of Asthma and Allergy · doi:10.2147/jaa.s290424 · Cited by 294
Self-citation
Metadata
- Authors
- Gevaert, P., Omachi, T. A., Corren, J., Mullol, J., Han, J., Lee, S. E., Kaufman, D., Ligueros-Saylan, M., Howard, M., Zhu, R., Owen, R., Wong, K., Islam, L., & Bachert, C.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 146
- Issue
- 3
- Pages
- 595-605
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W3034146395
- Cited by
- 739
- References
- 39
- FWCI
- 71.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.